I am increasingly convinced to problem lies in uncertainty about the long-term stability of the Vitrogro compound since I believe, I've implied previously, there is a novel protein involved. So the delay has nothing to do with the actual trial but lies in
mjshackl
I agree with your positive comment re trial size. It was set up and supervised by one of the world's leading expert on wound healing Prof Keith Harding who has been at the forefront of the field for 20 years. His experise includes clinical trials, clinical research, chronic wound healing, wound infection and he knew the purpose and desgned it accordingly - in particular, they recruited the most hard to heal patients which makes the results even more impressive.
I am increasingly convinced to problem lies in uncertainty about the long-term stability of the Vitrogro compound since I believe, I've implied previously, there is a novel protein involved. So the delay has nothing to do with the actual trial but lies in the manufacturing process - what data are needed, how stabilty can be tested and how quickly an appropriate quality assurance method can be approved and implemented.
Yes, TIS management has been substandard, they have got caught up in their own hype and believed the whole Vitrogro package to be unstoppable and as a result dropped their guard and tried to cut corners - in the end allowing others to ask the questions they should have asked and faced up to.
That said I don't think the answer is to get rid of them, a smack on the knuckles by all means - but they have a vast reservoir of knowledge that would be irreplacable in the short term. I'm sure the recent events have been a huge wake up call for them - they know what they have to do and have access to the experise they need and I think they will now pull their finger out.
Specul;ative investing is what it is - if you've been in TIS for a while what we bought for a few cents (actually the current price!) increased to around 80 cents - I only sold part because I was greedy!
TIS Price at posting:
11.5¢ Sentiment: Hold Disclosure: Held